TASS news agency on July 5 quoted Russian Industry and Trade Minister Denis Manturov as saying that, in addition to meeting domestic demand, Russia’s second vaccine, EpiVacCorona, has also received special attention from 7 countries in the world. world.
|The EpiVacCorona vaccine, developed by the Vector Institute, approved October 15, 2020. Photo: La Noticia|
“We are exploring export opportunities with EpiVacCorona vaccine. Besides Venezuela, 7 other countries are showing active interest in providing this vaccine. They are Mexico, Vietnam, Morocco, Pakistan, India. , Argentina and Bangladesh,” Manturov said.
Manturov previously said that the total production of CoviVac and EpiVacCorona vaccines is not enough to meet the demand for export abroad but can be met by the end of the year.
According to the minister, Russia can produce up to 14.5 million doses of EpiVacCorona vaccine this year. Currently, the country is giving priority to vaccinating Russians first due to the complicated situation.
It is known that Venezuela was the first country to choose to buy the EpiVacCorona vaccine from Russia after the country approved the vaccine in October 2020. EpiVacCorona, developed by the Vector Research Center for Viruses and Biotechnology, is Russia’s second vaccine. EpiVacCorona is made of 3 parts that make up the genome of the SARS-CoV-2 virus.
The data are based on phase 1 and 2 trials, published before the start of phase 3 trials with thousands of participants, which were up to 100% effective against COVID-19.
Venezuelan Foreign Minister Jorge Arreaza said Caracas hopes to launch domestic vaccine production in the future.
Mr. Rinat Maksyutov, Director of Vector’s Center for Virology and Biotechnology, emphasized that the Center’s EpiVacCorona vaccine is effective against all strains of viruses currently available: Alpha or British strains; Beta or South African strain; Gamma or Brazilian strain; and Delta or Indian strains.
“I can guarantee that there is no universal substitution for these four variants in the peptide sequence that is the basis of our vaccine. The shot will train the immune response of the vaccinated people against it. new variants by using stable parts of the coronavirus.”
In June, the Russian company Geropharm signed an agreement with the Venezuelan government for the supply of 10 million doses of the EpiVacCorona vaccine, with deliveries expected to begin in September.
The Kremlin denies that Russians are forced to vaccinate. The Russian president himself has stated that vaccination is still a personal choice.
A survey by the Levada Center in May found that 62 percent of Russians said they were not ready to get vaccinated. Meanwhile, anti-vaccination groups in Russia have openly opposed all vaccines, calling the pandemic a conspiracy theory.
Many Russians also believe that vaccines have been introduced to the market too soon or that the pandemic has been exaggerated. Also in the Levada survey, 55% of Russians said they were not particularly worried about contracting Covid-19.
Others who are reluctant to get the vaccine said they are waiting to see what the long-term side effects of the vaccine will be.
One of the other reasons many people delay vaccination is that they want to “wait for the Chumakov vaccine,” a new laboratory-made vaccine named after a famous Soviet-era doctor who helped develop the polio vaccine. oral form in the 1950s.